Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0309 | 0 | 0.5 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0309 | 0 | 0.5 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0309 | 0 | 0.5 |
Plasmodium falciparum | thioredoxin reductase | 0.0891 | 1 | 1 |
Trypanosoma brucei | trypanothione reductase | 0.0891 | 1 | 1 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0309 | 0 | 0.5 |
Plasmodium vivax | glutathione reductase, putative | 0.0891 | 1 | 1 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0891 | 1 | 1 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0891 | 1 | 1 |
Brugia malayi | Thioredoxin reductase | 0.0891 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0309 | 0 | 0.5 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0891 | 1 | 0.5 |
Treponema pallidum | NADH oxidase | 0.0309 | 0 | 0.5 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0309 | 0 | 0.5 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0309 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0309 | 0 | 0.5 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0891 | 1 | 1 |
Leishmania major | trypanothione reductase | 0.0891 | 1 | 1 |
Plasmodium falciparum | glutathione reductase | 0.0891 | 1 | 1 |
Toxoplasma gondii | thioredoxin reductase | 0.0891 | 1 | 1 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0891 | 1 | 1 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0891 | 1 | 1 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0309 | 0 | 0.5 |
Loa Loa (eye worm) | glutathione reductase | 0.0891 | 1 | 0.5 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0309 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.